Drug Profile

HY 133 - HYpharm GmbH

Alternative Names: HY-133

Latest Information Update: 12 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HYpharm GmbH
Class Antibacterials; Endolysins; Recombinant proteins
Mechanism of Action Cell wall modulators; Peptidoglycan modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Staphylococcal infections

Most Recent Events

12 Mar 2024 Preclinical development is ongoing in Staphylococcal infections in Germany (Intranasal)
05 Mar 2024 University Hospital Tuebingen plans a phase I trial for Staphylococcal infections in July 2024 (Intranasal, Spray) (NCT06290557)
28 Oct 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections in Germany (Intranasal, Gel)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com